Factory 99% Nintedanib Powder CAS 928326-83-4 Chemical Intermediate Anticancer Nintedanib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A546
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Nintedanib
• CAS: 928326-83-4
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anticancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Nintedanib
Appearance	White Powder
CAS NO.	928326-83-4
MF	C27H22F3N3O5
Storage	Keep in a cool, dry, dark location

 

Nintedanib is a chemical compound with the molecular formula C27H22F3N3O5. It belongs to the class of tyrosine kinase inhibitors (TKIs) and is specifically designed to target multiple receptors involved in angiogenesis and fibrosis.

 

1. Idiopathic Pulmonary Fibrosis (IPF): Nintedanib is approved for the treatment of IPF, a chronic, progressive lung disease characterized by alveolar damage and fibrosis.
2. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): It is also indicated for the treatment of SSc-ILD, a form of interstitial lung disease that occurs in patients with systemic sclerosis.
3. Cancer Treatment: In certain clinical trials, Nintedanib has been investigated for its potential in treating various types of cancer, particularly those involving angiogenesis and fibrosis.

1. Inhibition of Receptor Tyrosine Kinases: Nintedanib inhibits multiple receptor tyrosine kinases, including FGF receptors, which are crucial for angiogenesis and fibroblast proliferation.
2. Reduction of Fibrosis: By blocking these receptors, Nintedanib reduces the production and activity of fibroblasts, thereby slowing the progression of fibrosis in the lungs and other organs.
3. Improvement of Lung Function: In clinical studies, Nintedanib has been shown to improve lung function and reduce the rate of decline in forced vital capacity (FVC) in patients with IPF and SSc-ILD.